18:56 , Nov 16, 2018 |  BC Week In Review  |  Company News

ICER: asthma mAbs should be 50% cheaper for cost effectiveness

The Institute for Clinical and Economic Review (ICER) said the costs of five asthma mAbs would need to decrease by at least 50% to be cost effective in a final evidence report . ICER said...
17:57 , Sep 28, 2018 |  BC Week In Review  |  Company News

ICER finds asthma mAbs to be not cost-effective

In a draft evidence report , the Institute for Clinical and Economic Review (ICER) found that five biologics approved or in testing to treat asthma were not cost-effective compared with standard of care (SOC) therapies...
02:44 , Mar 10, 2018 |  BioCentury  |  Product Development

Virtual leap

Novartis AG’s decision to expand a collaboration with mobile technology and clinical trials management company Science 37 Inc. fits squarely within CEO Vasant Narasimhan’s oft-stated plans to use digital health to speed drug development. The...
20:51 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

DBV reports Phase I/II data for milk protein allergy therapy

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) reported preliminary data from the Phase II portion of the Phase I/II MILES trial to treat IgE-mediated cow’s milk protein allergy showing that the once-daily 300 µg dose of Viaskin...
19:21 , Jan 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Allergy Cell culture studies suggest a CD23-mimicking single-domain antibody against IgE could help treat allergy. The single-domain neutralizing antibody mimics CD23, the low-affinity Fc receptor for IgE, to bind IgE with a K d...
21:00 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

DBV's peanut allergy therapy meets Phase III safety endpoint

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Viaskin Peanut (DBV-712) met the primary safety endpoint in the Phase III REALISE trial to treat peanut allergy in patients ages 4-11. Specifically, Viaskin Peanut was well tolerated with...
22:58 , Nov 14, 2017 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Allergy Cell culture studies suggest a synthetic gene circuit that produces an IgE-blocking protein in response to allergy-promoting cytokines could help treat allergy. The synthetic gene circuit, expressed in a microencapsulated HEK cell line,...
18:00 , Aug 16, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling A profile containing a nine-gene signature in tumors and FCER1B protein levels in tumor mast cells could help predict survival in lung cancer. In 1,225 non-small cell lung cancer (NSCLC) patients, transcriptomic...
21:13 , Jul 13, 2017 |  BC Innovations  |  Translation in Brief

One shot at allergy

In a JCI Insight study, a cellular and gene therapy for allergy cured mice with a single dose, representing a new tolerizing approach to treat human allergy and other autoimmune diseases. Although the therapy could...
20:15 , May 25, 2017 |  BC Innovations  |  Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...